Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 89 (TMEM89) is a human protein encoded by the TMEM89 gene located on chromosome 3p21.31. The protein is 159 amino acids long, with two topological domains (extracellular and cytoplasmic) and a single transmembrane α-helix. TMEM89 is structurally rich in histidine, leucine, and tryptophan, and displays conserved regions among mammals but is uncharacterized functionally. It shows highest expression in the testis, with lower levels in several other tissues, and has predicted roles in protein–protein interactions, cell signaling, cytoskeletal organization, and membrane trafficking due to the presence of domains such as a predicted SH3-binding domain, N-myristylation site, and phosphorylation site. Clinically, TMEM89 has been proposed as a possible biomarker for upper tract urothelial carcinomas and may have modulatory roles in autism spectrum disorder severity and testicular germ cell tumor prognosis, but it is not currently considered a validated therapeutic target and has no known drug modulators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 89 (TMEM89).